Sharma A, et al. - In this analysis, researchers evaluated the effectiveness of a strategy of implantable cardioverter-defibrillator (ICD) plus medical therapy vs medical therapy alone among patients with heart failure (HF) and diabetes. They conducted a patient-level combined-analysis from a combined dataset that included 4 primary prevention ICD trials of patients with HF or severely reduced ejection fractions: Multicenter Automatic Defibrillator Implantation Trial I (MADIT I), MADIT II, Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE), and Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). This analysis included 3,359 patients. Outcomes suggested that primary prevention ICD in combination with medical therapy vs medical therapy alone was not markedly associated with a lower risk of all-cause death among patients with HF and diabetes.